ITP世界影响调查2.0:患者与医生对免疫性血小板减少症负担的认知
I-WISh 2.0调查15个国家1018例患者和431名医生,评估免疫性血小板减少症(ITP)及其治疗对患者的影响。约三分之一患者报告ITP对日常活动及家庭/社交生活高度影响,54%报告对情绪健康高度影响;48%患者 vs 29%医生认为疲劳常见且困扰。
要点
- ITP对患者日常活动、家庭社交及情绪健康造成显著负担,疲劳尤为突出。
- 患者比医生更常报告疲劳为常见且困扰的问题(48% vs 29%)。
核心结论
- I-WISh 2.0强调ITP患者面临广泛的疾病和治疗负担,尤其是疲劳的影响。
- 需共享决策以确保治疗目标与患者期望(包括健康相关生活质量)一致。
研究设计与样本
- ITP世界影响调查(I-WISh)2.0在15个国家调查1018例患者和431名医生。
主要发现
- 约三分之一患者报告ITP对日常活动及家庭/社交生活高度影响,54%报告对情绪健康高度影响。
- 48%患者 vs 29%医生报告疲劳常见且困扰。
- 三分之二患者处于稳定持续缓解,67%从未暂停治疗,但三分之二希望限制治疗时间或避免终身治疗。
临床怎么用
- 临床应关注ITP患者疲劳负担,并主动评估情绪健康和生活质量。
- 治疗决策应纳入共享决策,考虑患者对治疗时长和终身治疗的偏好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Limited data exist on how patients and physicians perceive immune thrombocytopenia (ITP) symptoms and treatment-related burden. I-WISh (ITP World Impact Survey) 2.0 surveyed 1018 patients and 431 physicians in 15 countries to characterize the impact of ITP and its treatments on patients. Approximately one-third of patients reported that ITP had a high impact on daily activities and family/social life, and 54% reported that it had a high impact on emotional wellbeing. Patients and physicians generally aligned on symptoms and treatment goals, but more patients (48%) than physicians (29%) reported fatigue as common and problematic. Ninety-seven percent of patients reported that they had received treatment for ITP, most commonly corticosteroids. Most patients and 54% of physicians were satisfied with available treatments, although patients reported treatment-related burdens. Twenty-eight percent confirmed they would have chosen a different treatment. Two-thirds of patients were in a stable, sustained remission, and most had never paused treatment (67%). Nevertheless, two-thirds of patients preferred limiting time on treatment and/or not being on lifelong treatment. I-WISh 2.0 emphasizes the extensive disease and treatment burden faced by patients living with ITP, especially the impact of fatigue. It also reminds us that shared decision-making is needed to ensure treatment goals are aligned with patient expectations, including health-related quality of life.
引用
- Cooper N, Bussel J, Ghanima W, et al. Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Survey (I-WISh) 2.0. Am J Hematol. 2026. PMID: 42237448. doi:10.1002/ajh.70379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。